Alok Maskara
Analyst · CJS Securities
Thank you, Heather. Please turn to Slide 10 for an update on the five key elements of our ongoing transformation plan. As we move to the end of the year, our simplification plan is nearly complete. We are ready to exit our SEC foreign private issuer status, and on January 1, 2019, we will become an SEC domestic issuer. Hence, these third quarter results are the last ones that we will be reporting under UK IFRS. Beginning with the fourth quarter and 2018 full year, our financial results will be reported under U.S. GAAP. To facilitate the transition included with the 6-K release yesterday, we have published supplementary financial information under U.S. GAAP. After the first of the year when we become a domestic issuer, we expect to publish a more comprehensive set of historical numbers. In addition, to provide greater transparency to our shareholders on executive compensation and corporate governance, we will become compliant with SEC's Section 16 and file the appropriate Forms 3, 4, and 5 in 2019. Annual proxy for 2018 will also be filed in April 2019. On the operational aspect of the transformation plan, I am pleased that our cultural transformation of driving results through pay for performance is gaining traction and delivering results. While there is more work to do, accountability is becoming a stronger value at Luxfer. As innovation remains a cornerstone for our growth, we are now implementing a stage-gate process for optimizing our ideas to launch funnel. Adoption of this process will enable us to develop new products faster and ensure that our products solve the need of a wider range of customers. In 2019, we will begin shipping our new ECLIPSE high-pressure composite cylinder, which is up to 20% lighter than comparable aluminum line cylinders and 3% lighter than composite line products. In addition, now with U.S. DOT approval, we hope to see growing demand for our unique L7X alloy, high-pressure aluminum cylinder, which can be filled up to 3,000 psi. In Elektron, in 2019, we will begin to see first revenues from our zirconium-based compound that is used as an ingredient in AstraZeneca's new Lokelma drug. This drug is used for the treatment of adults with elevated potassium levels in the bloodstream. On the productivity side, we are very pleased with our progress in meeting our $20 million cost-reduction goal by 2021. For the year-to-date, we have already achieved $4.7 million in annual savings, and we expect to recognize approximately $6 million in cost savings for the full year 2018. Finally, let me comment on our portfolio. Over the next few years, M&A will play a role in maximizing the value of the company for its shareholders. At any given time, we continue to evaluate a number of M&A opportunities to further our strategy of becoming a stronger, highly engineered advanced materials company. We screen these opportunities for strategic fit, expected return on invested capital and shareholder returns. In the meanwhile, our focus remains on deploying Luxfer's capital in those areas that deliver the highest risk-adjusted returns. Now please turn to Slide 11. Results for the quarter were very good as both growth and cost reductions were better than expected. Customer demand is increasing for innovative products such as SoluMag, and share recovery is occurring, notably in zirconium chemicals and alternative fuel cylinders. In addition, third quarter results benefited from improved operating trends in Superform. As a result, we are updating our full year guidance for adjusted earnings per share to approximately $1.65. This forecast contemplates ongoing favorable business activity, tempered by seasonal factors that affect our fourth quarter. Our outlook does not incorporate any further hurricane activity. At the same time, we are planning to take advantage of the current strength to accelerate spending on certain programs to support future growth and productivity. With the strong 2018 performance, we are confirming our targets of delivering 8% to 10% growth in our adjusted earnings in each of the next 3 years. Now please turn to Slide 12 for a wrap-up. The best days of Luxfer are ahead of us. We are making significant progress in 2018 towards our goal of building a stronger company focused on highly engineered advanced materials, serving attractive ends market. While we have made great strides in our cost-reduction efforts, there is more to do. We remain confident in delivering the $20 million cost-reduction goal by 2021. With the improved balance sheet, we are now better positioned to take advantage of opportunities that enhance our portfolio while maintaining our disciplined approach to capital allocation. Thank you for listening. We will now take questions.